Showing results (561-570 of 1,005) with videos related to

Sort By:
Pageof 101
Ejhaem|September 2, 2022
Global public awareness of Castleman disease and TAFRO syndrome between 2015 and 2021: A Google Trends analysisYoshito Nishimura, Midori Filiz Nishimura, David C Fajgenbaum, et al.
Ejhaem|September 2, 2022
The effect of HLA matching and donor relatedness on the risk of autoimmune haemolytic anaemia in haematopoietic stem cell transplant recipients: A systematic review and meta-analysisCassandra Kennedy, Denise E Jackson
Ejhaem|September 2, 2022
Outcomes of poor peripheral blood stem cell mobilizers with multiple myeloma at the first mobilization: A multicenter retrospective study in JapanYurie Miyamoto-Nagai, Naoya Mimura, Nobuhiro Tsukada, et al.
Ejhaem|September 2, 2022
Lower access to risk stratification tests and drugs, and worse survival of chronic lymphocytic leukaemia patients treated in public as compared to private hospitals in Brazil: A retrospective analysis of the Brazilian registry of chronic lymphocytic leukaemiaVerena Pfister, Fernanda de Morais Marques, Flavia Parra, et al.
Ejhaem|September 2, 2022
Non-factor therapies for bleeding disorders: A primer for the general haematologistDawn Swan, Johnny Mahlangu, Jecko Thachil
Ejhaem|September 2, 2022
Transcriptional profiles define drug refractory disease in myelomaYuan Xiao Zhu, Laura A Bruins, Xianfeng Chen, et al.
Ejhaem|September 2, 2022
Targetable alterations in primary extranodal diffuse large B-cell lymphomaStephanie E Weissinger, Rucha Dugge, Miriam Disch, et al.
Ejhaem|September 2, 2022
CB-103: A novel CSL-NICD inhibitor for the treatment of NOTCH-driven T-cell acute lymphoblastic leukemia: A case report of complete clinical response in a patient with relapsed and refractory T-ALLMichael Medinger, Till Junker, Dominik Heim, et al.
Ejhaem|September 2, 2022
Heterogeneous genetic and non-genetic mechanisms contribute to response and resistance to azacitidine monotherapyVasiliki Symeonidou, Marlen Metzner, Batchimeg Usukhbayar, et al.
Ejhaem|November 29, 2023
Outcomes of venetoclax combined with homoharringtonine and cytarabine in fit adults patients with de novo adverse-risk acute myeloid leukaemia: A single-centre retrospective analysisBao-Quan Song, Xin Kong, Yan Pu, et al.
Pageof 101